U.S. Banks Stock News

NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Why Gold Royalty (GROY) Is Down 8.0% After US$500 Million Shelf Filing And Profit Return

Gold Royalty Corp. recently filed a US$500 million universal shelf registration covering common and preferred shares, warrants, debt securities and units, while also reporting first-quarter 2026 sales of US$7.18 million and net income of US$1.77 million, reversing a net loss a year earlier. The combination of fresh capital-raising flexibility and a move into profitability, alongside new leadership roles in development and sustainability, could meaningfully influence how investors assess Gold...
NasdaqGS:MCHP
NasdaqGS:MCHPSemiconductor

Microchip Technology Expands Mission Critical Portfolio As Valuation Signals Diverge

Microchip Technology (NasdaqGS:MCHP) has launched the EX-423 Evacuated Miniature Crystal Oscillator for high-reliability timing applications. The company also introduced the LAN878x and LAN888x Single Pair Ethernet PHY transceiver families for automotive, industrial, and mission-critical systems. These products target sectors such as GPS tracking, military, medical devices, satellite communications, and industrial automation. Microchip Technology, trading at $93.85, has seen strong share...
NYSE:WK
NYSE:WKSoftware

Workiva EcoVadis Alliance Puts Scope 3 Data At Center Stage

Workiva (NYSE:WK) has announced a partnership with EcoVadis to link supplier carbon data with its reporting platform. The collaboration connects EcoVadis’ primary supplier emissions data to Workiva’s AI-powered system for supply chain decarbonization and sustainability reporting. The integration focuses on centralizing Scope 3 greenhouse gas data to support more accurate and auditable disclosures as climate reporting rules expand. Workiva, which offers a cloud platform for financial,...
NYSE:KRP
NYSE:KRPOil and Gas

Is Kimbell Royalty Partners (KRP) Prioritizing Payouts Over Earnings Resilience With Its Latest Distribution?

Kimbell Royalty Partners, LP recently reported first-quarter 2026 results showing revenue of US$65.54 million and net income of US$6.58 million, down from the prior year, while basic and diluted EPS from continuing operations came in at US$0.04. At the same time, the board approved a cash distribution of US$0.41 per common unit, equal to 75% of cash available for distribution for the quarter, highlighting the partnership’s continued emphasis on returning cash to unitholders despite softer...
NYSE:TEL
NYSE:TELElectronic

Is It Time To Reassess TE Connectivity (TEL) After Recent Share Price Weakness?

This article examines whether TE Connectivity at US$205.11 still offers value, or if most of the opportunity is already reflected in the price, and explains the key points in straightforward terms. The stock is down 0.5% over the last week and 12.4% over the last month, while the 1 year return is 26.9% and the 3 year return is 72.8%. These figures can influence how the current balance between risk and potential reward is perceived. Recent coverage has highlighted TE Connectivity's role as a...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

A Look At Apellis Pharmaceuticals (APLS) Valuation After The Biogen Acquisition Announcement

Why Apellis Pharmaceuticals (APLS) Is On Investors’ Radar Apellis Pharmaceuticals (APLS) has drawn fresh attention after being acquired by Biogen, with the company now operating as a subsidiary as of May 14, 2026, while its stock continues to trade independently. See our latest analysis for Apellis Pharmaceuticals. At a share price of US$41.03, Apellis has seen a sharp 90 day share price return of 89.08% and a 1 year total shareholder return of 135.13%. However, the 3 year total shareholder...
NasdaqGM:SEPN
NasdaqGM:SEPNPharmaceuticals

Assessing Septerna (SEPN) Valuation After Strong Q1 Results And Progress Toward Breakeven

Septerna (SEPN) drew fresh attention after first quarter 2026 results showed sales of US$26.52 million and a narrower net loss of US$8.64 million. Analysts view these developments as progress toward breakeven. See our latest analysis for Septerna. The stock has been volatile around these results, with a 1-day share price return showing a 4.84% decline after the earnings release, a 7-day share price return showing a 12.90% gain, and a 1-year total shareholder return of about 1.7x, which points...
NYSE:APH
NYSE:APHElectronic

Amphenol Joins EBO Standard To Shape AI Data Center Connectivity

Amphenol (NYSE:APH) has joined a new multi source agreement to standardize expanded beam optical connectivity for AI data centers. The group includes 3M, AMD, Cisco, Meta and Arista Networks, collaborating on open, interoperable EBO specifications. The initiative targets next generation data center infrastructure used by hyperscale and enterprise customers. Amphenol is a large connector and interconnect systems supplier, with products that feed into data centers, communications, automotive...
NasdaqGS:FWON.K
NasdaqGS:FWON.KEntertainment

Is Formula One Group (FWON.K) Pricing Reflect Its Slowing Share Gains And Premium P/E?

Wondering if Formula One Group at around US$89.54 is priced fairly or if the market is missing something? This article looks at what the current valuation signals might be telling you. The stock is down about 5.2% over the past week and 1.0% over the past month, with returns also lower year to date at 8.7% and over the last year at 7.4%, even though the 3 year and 5 year returns sit at 26.4% and 108.4% respectively. Recent headlines around Formula One Group have kept attention on the long...
NYSEAM:CTGO
NYSEAM:CTGOMetals and Mining

A Look At Contango Silver & Gold (CTGO) Valuation After Lucky Shot Progress And Q1 2026 Results

Contango Silver & Gold (CTGO) is back in focus after Q1 2026 results showed a net loss of US$14.31 million, alongside progress at the Lucky Shot project and the integration of Dolly Varden’s Kitsault Valley assets. See our latest analysis for Contango Silver & Gold. The stock has pulled back sharply in the short term, with the 7 day share price return down 17.47% and the year to date share price return down 16.42%. The 1 year total shareholder return is up 52.03%, which suggests that earlier...
NYSE:ALH
NYSE:ALHMachinery

Is It Time To Reassess Alliance Laundry Holdings (ALH) After Its Recent Share Price Swings?

If you are wondering whether Alliance Laundry Holdings at around US$23.83 is priced attractively or not, you will want to look closely at what the valuation signals are really saying. The stock is up 11.4% year to date, even though it has fallen 6.2% over the last week and 4.7% over the past month, which suggests sentiment around the shares has been shifting over the short term. Recent coverage has focused on Alliance Laundry Holdings in the context of its listing and positioning within the...
NYSE:KAI
NYSE:KAIMachinery

Kadant (KAI) Is Down 6.2% After Raising Revenue Outlook But Cutting GAAP EPS Guidance – What's Changed

Kadant Inc. recently reported first-quarter 2026 results, with sales rising to US$281.51 million and net income reaching US$25.51 million, while also issuing updated guidance reflecting its latest acquisition. The company raised its full-year 2026 revenue outlook but trimmed GAAP EPS guidance to account for acquisition-related costs, highlighting the trade-off between growth and near-term profitability. We’ll now examine how Kadant’s raised full-year revenue guidance, despite lower GAAP EPS...
NYSE:QXO
NYSE:QXOTrade Distributors

QXO (QXO) Is Down 13.0% After Big Revenue Jump But Quarterly Loss Widens - What's Changed

QXO, Inc. recently filed an US$810.01 million shelf registration for 45,659,927 common shares tied to an ESOP-related offering and reported first-quarter 2026 results showing sales of US$1,730.2 million and a net loss of US$227.1 million. The combination of very large year-on-year sales growth with a swing from prior-year profit to a basic loss per share of US$0.35 raises important questions about QXO’s current profitability profile. We will now examine how QXO’s very large revenue increase...
NYSE:CNA
NYSE:CNAInsurance

A Look At CNA Financial (CNA) Valuation After Earnings Miss And BofA Downgrade

CNA Financial (CNA) is back in focus after a softer first quarter and cautious commentary from management, followed by a downgrade from BofA Securities that has added to pressure on the stock. See our latest analysis for CNA Financial. The stock recently touched a new 52 week low at $42.75, and despite a 3 year total shareholder return of 40.60%, the 30 day share price return is down 7.82% and year to date share price momentum has softened, reflecting investor concern after the first quarter...
NYSE:WCC
NYSE:WCCTrade Distributors

Is It Too Late To Consider WESCO International (WCC) After Its 109% One-Year Rally?

If you are wondering whether WESCO International stock still offers value after its strong run, the next sections will walk through what the current price might be implying. The stock closed at US$358.72, with returns of 1.0% over the past week, 17.3% over the past month, 42.3% year to date and 108.7% over the past year, plus very large gains over 3 and 5 years of 174.8% and 255.8% respectively. Those figures can change how you think about risk and reward today. Recent coverage has focused...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

GeneDx Fraud Probes And Guidance Cut Put Valuation Gap In Focus

GeneDx Holdings (NasdaqGS:WGS) reported a significant Q1 2026 revenue miss and sharply cut its full year guidance. Following this update, two law firms launched investigations into potential securities fraud linked to the company’s prior commentary on revenue and profitability. The investigations focus on whether recent statements were materially misleading, especially given the reaffirmation of optimistic targets shortly before the guidance change. These events came alongside a steep fall...
NYSE:GBX
NYSE:GBXMachinery

Toronto Dominion Takes 6% Passive Stake In Greenbrier As Valuation Stretches

The Toronto Dominion Bank and its affiliate TD Securities have disclosed a passive ownership stake of more than 6% in Greenbrier Companies. The position was reported in a Schedule 13G/A filing, indicating a sizeable institutional holding in NYSE:GBX common stock. The filing signals a meaningful change in Greenbrier Companies' shareholder base involving a large financial institution. For existing and potential shareholders, this new stake comes as NYSE:GBX trades at around $47.64, with the...
NYSE:BDC
NYSE:BDCElectronic

Belden’s RUCKUS Deal Recasts Growth Story In AI Ready Networking

Belden (NYSE:BDC) announced an agreement to acquire RUCKUS Networks for approximately US$1.85b. The deal is intended to position Belden as a provider of end to end IT and operational technology networking solutions. The transaction is expected to immediately affect Belden's financial profile, including margins and earnings. The acquisition expands Belden's reach into AI focused networking markets that the company views as high growth areas. Belden, known for its signal transmission and...
NYSE:ULS
NYSE:ULSProfessional Services

UL Solutions Scooter Warning Puts Safety Marks And Valuation In Focus

UL Solutions (NYSE:ULS) issued a public warning about certain electric scooters carrying unauthorized UL certification marks. The company said these scooters may pose safety risks for consumers and do not reflect its official testing or certification. The alert focuses attention on brand protection and the integrity of UL Solutions' safety marks across fast growing consumer electronics categories. For investors, this update relates directly to what UL Solutions sells: independent safety...
NYSE:RGA
NYSE:RGAInsurance

What Reinsurance Group of America (RGA)'s Record Q1 Earnings and New Shelf Registration Mean For Shareholders

Earlier in May 2026, Reinsurance Group of America filed an omnibus shelf registration covering multiple securities and reported first-quarter revenue of US$6,494 million and net income of US$330 million, alongside affirming a quarterly dividend of US$0.93 per share. The company’s record profitability, supported by favorable claims experience across regions and disciplined capital deployment, underpins its flexibility to raise capital and return cash to shareholders through varied...
NYSE:JEF
NYSE:JEFCapital Markets

Is Jefferies Financial Group (JEF) Fully Priced After Its Recent Share Price Strength

Wondering if Jefferies Financial Group at around US$52 per share offers good value right now, or if most of the opportunity is already on the table. The stock is down about 1.4% over the past week, up 11.5% over the past month, roughly flat with a 2.0% gain over the last year, and has returned 85.6% over three years and 97.7% over five years. These moves have come alongside ongoing interest in capital markets and financial services companies, with Jefferies often in focus when investors...
NasdaqGM:IVVD
NasdaqGM:IVVDBiotechs

Invivyd (IVVD) Q1 Loss Of US$41.4 Million Reinforces Bearish Unprofitability Narrative

Invivyd (IVVD) has released its Q1 2026 numbers with revenue of about US$13.7 million and a basic EPS loss of US$0.13, alongside a trailing 12 month net loss of US$77.6 million. The company has seen revenue move from US$25.4 million in Q4 2024 on a trailing 12 month basis to US$55.9 million in the latest trailing period, while trailing basic EPS has shifted from a loss of US$1.43 to a loss of US$0.35. Investors are therefore looking at a business where top line momentum is meeting still heavy...
NasdaqGS:TYRA
NasdaqGS:TYRABiotechs

Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?

Tyra Biosciences, Inc. recently reported first-quarter 2026 results showing a wider net loss of US$39.31 million and basic loss per share of US$0.64, while highlighting progress across three Phase 2 trials for its lead candidate dabogratinib and a cash balance of US$383.5 million supporting operations into the second half of 2028. An interesting angle for investors is how Tyra’s “dabogratinib 3×3” plan concentrates resources on three FGFR3-driven indications, potentially shaping its future...
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements

Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that could influence how investors view the stock. See our latest analysis for Humacyte. The share price has been volatile, with a 1 month share price return of 26.36% but a 1 year total shareholder return that is down 58.48%. This reflects shifting sentiment as investors weigh fresh capital raises,...